Accumulation of a bioactive triterpene saponin fraction of Quillaja brasiliensis leaves is associated with abiotic and biotic stresses

The saponins from leaves of Quillaja brasiliensis, a native species from Southern Brazil, show structural and functional similarities to those of Quillaja saponaria barks, which are currently used as adjuvants in vaccine formulations. The accumulation patterns of an immunoadjuvant fraction of leaf triterpene saponins (QB-90) in response to stress factors were examined, aiming at understanding the regulation of accumulation of these metabolites. The content of QB-90 in leaf disks was significantly increased by application of different osmotic stress agents, such as sorbitol, sodium chloride and polyethylene glycol in isosmotic concentrations. Higher yields of bioactive saponins were also observed upon exposure to salicylic acid, jasmonic acid, ultrasound and UV-C light. Experiments with shoots indicated a significant increase in QB-90 yields with moderate increases in white light irradiance and by mechanical damage applied to leaves. The increased accumulation of these terpenes may be part of a defense response. The results herein described may contribute to further advance knowledge on the regulation of accumulation of bioactive saponins, and at defining strategies to improve yields of these useful metabolites.

Application of Quillaja saponaria extracts as oral adjuvants for plant-made vaccines

Extracts from the Quillaja saponaria tree are known to provide immune potentiating responses and, hence, can be useful as adjuvants. Partial purification from the crude (food-grade) extract results in Quil A, which is contained in several veterinary vaccines. Further purification can provide concentrated saponin fractions such as QS-21, which is currently under investigation as a potential adjuvant for use in humans. Purified saponins have proven safe and effective when injected and have significantly enhanced the efficacy of some oral vaccines under clinical investigation. Toxicity of the food-grade extract from Quillaja saponaria has limited its use as a parenteral adjuvant; however, this toxicity seems to be abated when delivered orally. It is commonly used within the food and beverage industries and has no documented toxicity in humans at the present levels of consumption. Use of transgenic plants has been proposed as an alternative system for oral vaccine production and administration, and it is likely that an oral adjuvant will be required in most cases. Food-grade saponins have significant advantages for use with plant-made vaccines and are likely to provide a broad adjuvant effect due to the multiple saponin components. A review of the origin, production, biological activity, toxicity and use in the food industry is provided for Quillaja saponaria extract. Previous evaluation of this adjuvant in preclinical studies with plant made vaccines is discussed and a proposed level of experimental use in humans is provided.